Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Debt (2016 - 2025)

Sanofi (SNY) has disclosed Non-Current Debt for 11 consecutive years, with $16.6 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 31.63% to $16.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.6 billion through Dec 2025, up 31.63% year-over-year, with the annual reading at $16.1 billion for FY2025, 26.14% up from the prior year.
  • Non-Current Debt hit $16.6 billion in Q4 2025 for Sanofi, up from $12.6 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $19.6 billion in Q4 2021 to a low of $12.6 billion in Q4 2024.
  • Historically, Non-Current Debt has averaged $15.9 billion across 5 years, with a median of $15.4 billion in 2023.
  • Biggest five-year swings in Non-Current Debt: decreased 22.62% in 2022 and later soared 31.63% in 2025.
  • Year by year, Non-Current Debt stood at $19.6 billion in 2021, then fell by 22.62% to $15.2 billion in 2022, then increased by 1.84% to $15.4 billion in 2023, then decreased by 18.38% to $12.6 billion in 2024, then skyrocketed by 31.63% to $16.6 billion in 2025.
  • Business Quant data shows Non-Current Debt for SNY at $16.6 billion in Q4 2025, $12.6 billion in Q4 2024, and $15.4 billion in Q4 2023.